A PHASE III, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA
This study enrolls adults with esophageal cancer. The purpose of this study is to compare the effects of different combinations of medications to treat this cancer. Atezolizumab and tiragolumab are experimental drugs, which means the U.S. Food and Drug Administration (FDA) has not approved them, alone or in combination, for the treatment of esophageal cancer.
In this study, you will get either atezolizumab plus tiragolumab, atezolizumab plus placebo, or double placebo. A placebo looks like a drug but has no active ingredient. You will take them for about 1 year and be in the study for up to 2 years. You will have study visits to our office every 21 days for 12 months. We will ask you questions about your health throughout the study. Compensation is not available but reasonable travel costs may be reimbursed. Study takes place at Kaleida Health facilities.
This study will evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in patients with locally advanced esophageal squamous cell carcinoma (or those who are unable or unwilling to undergo surgery) and who have completed definitive concurrent chemoradiation therapy. Site For YO42137_SKYSCRAPER-07
Adults ages 18+.
Diagnosed with esophageal cancer (squamous cell carcinoma of the esophagus) in stage II-IIVA.
The cancer is unresectable, which means you are unable to unwilling to have surgery.
You have received chemoradiotherapy and your disease did not worsen.
Let us know how the study team can reach you.
If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email firstname.lastname@example.org and someone will assist you.